References

The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030

10.1016/s0140-6736(21)00684-x · 2021 · External reference

Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015

10.1016/j.jacc.2017.04.052 · 2017 · External reference

Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging

10.1210/jc.2011-3362 · 2012 · External reference

Premature menopause or early menopause: long-term health consequences

10.1016/j.maturitas.2009.08.003 · 2010 · External reference

10.1016/b978-0-323-47912-7.00014-7

10.1016/b978-0-323-47912-7.00014-7 · 2019 · External reference

Molecular and genetic insights into human ovarian aging from single-nuclei multi-omics analyses

10.1038/s43587-024-00762-5 · 2025 · External reference

Comparison of transitional vs surgical menopause on monoamine and amino acid levels in the rat brain

10.1016/j.mce.2018.05.003 · 2018 · External reference

The role of genetic factors in age at natural menopause

10.1093/humrep/16.9.2014 · 2001 · External reference

Estrogen as a key regulator of energy homeostasis and metabolic health

10.1016/j.biopha.2022.113808 · 2022 · External reference

The impact of estrogen deficiency on liver metabolism: implications for hormone replacement therapy

10.1210/endrev/bnaf018 · 2025 · External reference

Dyslipidemia in midlife women: approach and considerations during the menopausal transition

10.1016/j.maturitas.2022.08.001 · 2022 · External reference

Molecular and cellular basis of cardiovascular gender differences

10.1126/science.1112062 · 2005 · External reference

Atherosclerotic plaque stabilization and regression: a review of clinical evidence

10.1038/s41569-023-00979-8 · 2024 · External reference

The menopausal transition period and cardiovascular risk

10.1038/s41569-023-00926-7 · 2024 · External reference

Diagnosis and management of menopause: the National Institute of Health and Care Excellence (NICE) guideline

10.1001/jamainternmed.2016.2761 · 2016 · External reference

Body composition and cardiometabolic health across the menopause transition

10.1002/oby.23289 · 2022 · External reference

Can inhibin b reflect ovarian reserve of healthy reproductive age women effectively?

10.3389/fendo.2021.626534 · 2021 · External reference

Study on gut microbiota and metabolomics in postmenopausal women

10.1186/s12905-024-03448-7 · 2024 · External reference

Higher values of hepatic lipase activity in postmenopause: relationship with atherogenic intermediate density and low density lipoproteins

10.1097/00042192-200101000-00009 · 2001 · External reference

Lipoprotein subclasses and endogenous sex hormones in women at midlife

10.1194/jlr.p049064 · 2014 · External reference

Circulating small dense LDL, endothelial injuring factors and fibronectin in healthy postmenopausal women

10.1016/j.cca.2007.03.004 · 2007 · External reference

Hepatic VLDL-TG production and MTP gene expression are decreased in ovariectomized rats: effects of exercise training

10.1055/s-0030-1267173 · 2010 · External reference

Mechanisms regulating LDL metabolism in subjects on peroral and transdermal estrogen replacement therapy

10.1161/01.atv.20.4.1101 · 2000 · External reference

Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat

10.1172/jci118883 · 1996 · External reference

Estrogen regulation of the scavenger receptor class B gene: anti-atherogenic or steroidogenic, is there a priority?

10.1016/j.mce.2005.10.005 · 2006 · External reference

Relationship between lipoproteins, thrombosis, and atrial fibrillation

10.1093/cvr/cvab017 · 2022 · External reference

Lipoprotein-based drug delivery

10.1016/j.addr.2020.08.003 · 2020 · External reference

Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations

10.1038/s41581-021-00423-5 · 2021 · External reference

Overproduction of very low–density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome

10.1161/atvbaha.107.160192 · 2008 · External reference

HDL and reverse cholesterol transport: basic mechanisms and their roles in vascular health and disease

10.1161/circresaha.119.312617 · 2019 · External reference

The emergence of the metabolic syndrome with menopause

10.1210/jc.2003-030242 · 2003 · External reference

Menopausal Hormone Therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications

10.1210/er.2016-1146 · 2017 · External reference

The effect of estrogen on the lipoprotein lipase activity of rat adipose tissue

10.1172/jci108015 · 1975 · External reference

Differences in adipose tissue metabolism between postmenopausal and perimenopausal women

10.1210/jc.2001-012034 · 2002 · External reference

Metabolic characterization of menopause: cross-sectional and longitudinal evidence

10.1186/s12916-018-1008-8 · 2018 · External reference

Unraveling the associations of age and menopause with cardiovascular risk factors in a large population-based study

10.1186/s12916-016-0762-8 · 2017 · External reference

Lipid changes during the menopause transition in relation to age and weight: the study of Women's health across the nation

10.1093/aje/kwp043 · 2009 · External reference

Menopausal status and risk factors for cardiovascular disease

10.1046/j.1365-2796.1999.00547.x · 1999 · External reference

Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy: a prospective British birth cohort study

10.1111/j.1471-0528.2005.00416.x · 2005 · External reference

Menopausal stages and serum lipid and lipoprotein abnormalities in middle-aged women

10.1016/j.maturitas.2014.12.016 · 2015 · External reference

Menopause modulates the circulating metabolome: evidence from a prospective cohort study

10.1093/eurjpc/zwac060 · 2022 · External reference

Effects of menopause on trends of Serum cholesterol, blood pressure, and body mass Index

10.1161/01.cir.94.1.61 · 1996 · External reference

Effects of menopause, gender and age on lipids and high-density lipoprotein cholesterol subfractions

10.1016/j.maturitas.2015.02.262 · 2015 · External reference

Menopause-related changes in lipoproteins and some other cardiovascular risk factors

10.1093/ije/19.1.42 · 1990 · External reference

The effect of menopause on blood lipid and lipoprotein levels. The Icarus Study Group

10.1016/s0021-9150(99)00315-9 · 1999 · External reference

The effect of the menopausal transition on body composition and cardiometabolic risk factors: a Montreal-Ottawa new emerging team group study

10.1097/gme.0b013e318240f6f3 · 2012 · External reference

Menopause with cardiovascular disease and its risk factors among rural Chinese women in Beijing: a population-based study

10.1016/j.maturitas.2012.02.013 · 2012 · External reference

Influence of age and sex on longitudinal metabolic profiles and body weight trajectories in the UK Biobank

10.1093/ije/dyae055 · 2024 · External reference

Lipid profile changes during the menopausal transition

10.1097/gme.0000000000001532 · 2020 · External reference

Plasma metabolic profiles in women are menopause dependent

10.1371/journal.pone.0141743 · 2015 · External reference

Circulating oxidized LDL is associated with parameters of the metabolic syndrome in postmenopausal women

10.1016/j.atherosclerosis.2006.03.036 · 2007 · External reference

Markers of increased cardiovascular risk in postmenopausal women: focus on oxidized-LDL and HDL subpopulations

10.1155/2013/724706 · 2013 · External reference

Physiological bases for the superiority of apolipoprotein b over low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol as a marker of Cardiovascular Risk

10.1161/jaha.122.025858 · 2022 · External reference

Lipid and lipoprotein biomarkers and the risk of ischemic stroke in postmenopausal women

10.1161/strokeaha.111.641324 · 2012 · External reference

A metabolic view on menopause and ageing

10.1038/ncomms5708 · 2014 · External reference

HDL (High-Density Lipoprotein) subclasses, lipid content, and function trajectories across the menopause transition: SWAN-HDL study

10.1161/atvbaha.120.315355 · 2021 · External reference

Menopause is associated with postprandial metabolism, metabolic health and lifestyle: the ZOE PREDICT study

10.1016/j.ebiom.2022.104303 · 2022 · External reference

Age-dependent sex differences in cardiometabolic risk factors

10.1038/s44161-022-00131-8 · 2022 · External reference

Low-density lipoprotein subclasses over the menopausal transition and risk of coronary calcification and carotid atherosclerosis: the SWAN Heart and HDL ancillary studies

10.1097/gme.0000000000002245 · 2023 · External reference

Earlier age at menopause, plasma metabolome, and risk of premature mortality

10.3390/metabo14110571 · 2024 · External reference

The impact of reproductive factors on the metabolic profile of females from menarche to menopause

10.1038/s41467-023-44459-6 · 2024 · External reference

Years since menopause and its metabolomic signature with biological aging in women at midlife: a population-based study

10.1038/s41514-025-00249-6 · 2025 · External reference

Age- and sex-specific lipoprotein profiles in general and cardiometabolic population cohorts

10.1016/j.ebiom.2025.106021 · 2025 · External reference

Integrating menopause duration and plasma metabolomics enhances cardiovascular risk stratification in aging women

10.1038/s41514-025-00323-z · 2026 · External reference

Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?

10.1016/j.jacc.2009.10.009 · 2009 · External reference

Lipid profile differences during menopause: a review with meta-analysis

10.1097/gme.0000000000001403 · 2019 · External reference

Trajectories of blood lipids profile in midlife women: does menopause matter?

10.1161/jaha.123.030388 · 2023 · External reference

Progression of metabolic syndrome severity during the menopausal transition

10.1161/jaha.116.003609 · 2016 · External reference

Age at menopause in relationship to lipid changes and subclinical carotid disease across 20 years: study of women's health across the nation

10.1161/jaha.121.021362 · 2021 · External reference

The effect of menopause on lipoprotein (a) concentrations: a systematic review and meta-analysis

10.1016/j.maturitas.2022.09.012 · 2023 · External reference

Lipoprotein (a), hormone replacement therapy, and risk of future cardiovascular events

10.1016/j.jacc.2008.04.009 · 2008 · External reference

Changes in lipoprotein subfractions following menopause in the Longitudinal Study of Adult Health (ELSA-Brasil)

10.1016/j.maturitas.2019.09.005 · 2019 · External reference

Metabolic health, menopause, and physical activity—a 4-year follow-up study

10.1038/s41366-021-01022-x · 2022 · External reference

Serum metabolomic profiles associated with postmenopausal hormone use

10.1007/s11306-018-1393-1 · 2018 · External reference

A mediating role of visceral adipose tissue on the association of health behaviours and metabolic inflammation in menopause: a population-based cross-sectional study

10.1038/s41598-025-85134-8 · 2025 · External reference

C-reactive protein is associated with aortic stiffness in a cohort of African American and white women transitioning through menopause

10.1097/gme.0b013e31821f81c2 · 2011 · External reference

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

10.1093/eurheartj/ehz455 · 2020 · External reference

Apolipoprotein B vs low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as the primary measure of apolipoprotein B lipoprotein-related risk: the debate is over

10.1001/jamacardio.2021.5080 · 2022 · External reference

Impact of LDL-C and Apolipoprotein B level discordance and associated lipoprotein particle alterations on Cardiovascular outcomes in a large primary prevention population

10.1093/eurjpc/zwaf750 · 2025 · External reference

Apob: the power of physiology to transform the prevention of cardiovascular disease

10.1161/circresaha.119.315019 · 2019 · External reference

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

10.1016/j.jacc.2018.11.003 · 2019 · External reference

Apob in clinical care: pro and con

10.1016/j.atherosclerosis.2018.11.001 · 2019 · External reference

Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases

10.3109/10408363.2014.992063 · 2015 · External reference

Menopausal status and physical activity are independently associated with cardiovascular risk factors of healthy middle-aged women: cross-sectional and longitudinal evidence

10.3389/fendo.2019.00589 · 2019 · External reference

Age at period cessation and trajectories of cardiovascular risk factors across mid and later life

10.1136/heartjnl-2019-315754 · 2020 · External reference

HDL and the menopause

10.1097/mol.0000000000000432 · 2017 · External reference

Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe

10.1136/jech.56.suppl_1.i19 · 2002 · External reference

Lipids, menopause, and early atherosclerosis in Study of Women's Health Across the Nation Heart women

10.1097/gme.0b013e3181f6480e · 2011 · External reference

Increase HDL-C level over the menopausal transition is associated with greater atherosclerotic progression

10.1016/j.jacl.2016.04.008 · 2016 · External reference

The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the evidence

10.1111/j.1365-2796.2006.01643.x · 2006 · External reference

Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—experience from the Swedish AMORIS cohort: a cohort study

10.1371/journal.pmed.1003853 · 2021 · External reference

Comparison of apolipoprotein (apoB/apoA-I) and lipoprotein (Total Cholesterol/HDL) ratio determinants. Focus on obesity, diet and alcohol intake

10.1371/journal.pone.0040878 · 2012 · External reference

Apolipoprotein A-1 regulates osteoblast and lipoblast precursor cells in mice

10.1038/labinvest.2016.51 · 2016 · External reference

Label-free quantitative proteomics in serum reveals candidate biomarkers associated with low bone mineral density in Mexican postmenopausal women

10.1007/s11357-023-00977-1 · 2024 · External reference

Association of apolipoprotein A1 with osteoporosis: a cross-sectional study

10.1186/s12891-023-06264-6 · 2023 · External reference

ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator

10.1186/s12944-017-0619-y · 2017 · External reference

Relationship between osteoporosis and cardiovascular disease in postmenopausal women

10.1359/jbmr.050711 · 2005 · External reference

The link between osteoporosis and cardiovascular disease

2008 · External reference

Association between very low-density lipoprotein cholesterol (VLDL-C) and carotid intima-media thickness in postmenopausal women without overt cardiovascular disease and on LDL-C target levels

10.3390/jcm9051422 · 2020 · External reference

Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study

10.1161/01.cir.87.4.1135 · 1993 · External reference

Healthy lifestyle, lipoprotein (a) levels and the risk of coronary artery disease

10.1111/eci.14093 · 2024 · External reference

Lipoprotein(a) and cardiovascular risk prediction among women

10.1016/j.jacc.2018.04.060 · 2018 · External reference

Effect of C-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE trial

10.1001/jamacardio.2020.2413 · 2020 · External reference

Lipoprotein(a), menopausal hormone therapy, and risk of coronary heart disease in postmenopausal individuals

10.1001/jamacardio.2022.0716 · 2022 · External reference

Discrimination and net-reclassification of cardiovascular disease risk with lipoprotein (a) levels: the ATTICA study (2002–2022)

10.1016/j.jacl.2024.04.126 · 2024 · External reference

AHA PREVENT equations and lipoprotein (a) for cardiovascular disease risk: insights from MESA and the UK Biobank

10.1001/jamacardio.2025.1603 · 2025 · External reference

Discrimination and net reclassification of cardiovascular risk with lipoprotein (a) prospective 15-year outcomes in the Bruneck study

10.1016/j.jacc.2014.03.061 · 2014 · External reference

Lipoprotein (a) atherosclerotic cardiovascular disease risk score development and prediction in primary prevention from real-world data

10.1161/circgen.124.004631 · 2025 · External reference

Measurement issues related to lipoprotein heterogeneity

10.1016/s0002-9149(02)02632-2 · 2002 · External reference

Determining the status of small dense low-density lipoprotein cholesterol level in women undergoing menopausal transition

2024 · External reference

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

10.1093/eurheartj/ehz962 · 2020 · External reference

Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women

10.1161/circulationaha.108.816181 · 2009 · External reference

High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study

10.1186/ar3842 · 2012 · External reference

Menopausal status and abdominal obesity are significant determinants of hepatic lipid metabolism in women

10.1161/jaha.115.002258 · 2015 · External reference

Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology

10.1161/circresaha.115.306249 · 2016 · External reference

Triglyceride-rich lipoproteins and cardiovascular diseases

2024 · External reference

Triglycerides: a reappraisal

10.1016/j.tcm.2017.03.004 · 2017 · External reference

Metabolic profiling of charged metabolites in association with menopausal status in Japanese community-dwelling midlife women: Tsuruoka Metabolomic Cohort Study

10.1016/j.maturitas.2021.10.004 · 2022 · External reference

Differences in the fatty acid metabolism of visceral adipose tissue in postmenopausal women

10.1097/gme.0b013e318296431a · 2014 · External reference

Metabolic predictors of incident coronary heart disease in women

10.1161/circulationaha.117.029468 · 2018 · External reference

Alterations in postmenopausal plasmatic lipidome

10.1371/journal.pone.0203027 · 2018 · External reference

Differential metabolomics networks analysis of menopausal status

10.1371/journal.pone.0222353 · 2019 · External reference

High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: evidence from two large population cohort studies

10.1371/journal.pbio.3000870 · 2020 · External reference

Metabolomic profiles associated with all-cause mortality in the Women's Health Initiative

10.1093/ije/dyz211 · 2020 · External reference

Serum metabolic profiles of Chinese women with perimenopausal obesity explored by the untargeted metabolomics approach

10.3389/fendo.2021.637317 · 2021 · External reference

CVD and oxidative stress

10.3390/jcm6020022 · 2017 · External reference

Assessing the causal association of glycine with risk of cardio-metabolic diseases

10.1038/s41467-019-08936-1 · 2019 · External reference

Plasma glycine and risk of acute myocardial infarction in patients with suspected stable angina pectoris

10.1161/jaha.115.002621 · 2015 · External reference

Metabolic signatures of insulin resistance in 7,098 young adults

10.2337/db11-1355 · 2012 · External reference

Circulating branched-chain amino acids and incident cardiovascular disease in a prospective cohort of US women

10.1161/circgen.118.002157 · 2018 · External reference

Evaluating the association between amino acid and acylcarnitine profiles and different levels of coronary artery disease risk in postmenopausal women using targeted metabolomics technique

10.1097/gme.0000000000002016 · 2022 · External reference

High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis

10.1093/eurheartj/ehs020 · 2012 · External reference

Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans

10.1172/jci44442 · 2011 · External reference

Metabolome-wide Mendelian randomization for age at menarche and age at natural menopause

10.1186/s13073-024-01322-7 · 2024 · External reference

Proinflammatory and anti-inflammatory cytokine changes related to menopause

2014 · External reference

Glyca, a novel biomarker of systemic inflammation and cardiovascular disease risk

10.1186/s12967-017-1321-6 · 2017 · External reference

Glyca, a novel pro-inflammatory glycoprotein biomarker is associated with mortality: results from the PREVEND study and meta-analysis

10.1111/joim.12953 · 2019 · External reference

Comparison of the stability of glycoprotein acetyls and high sensitivity C-reactive protein as markers of chronic inflammation

10.1111/imm.13739 · 2024 · External reference

Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in type 2 diabetes mellitus

10.1161/circulationaha.116.023233 · 2016 · External reference

The “newer” progestogens and postmenopausal hormone therapy (HRT)

10.1016/j.jsbmb.2013.12.003 · 2014 · External reference

Hormone-replacement therapy: current thinking

10.1038/nrendo.2016.164 · 2017 · External reference

Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort

10.1002/ijc.20710 · 2005 · External reference

Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study

10.1007/s10549-007-9523-x · 2008 · External reference

The impact of micronized progesterone on breast cancer risk: a systematic review

10.1080/13697137.2017.1421925 · 2018 · External reference

Relationship between menopausal hormone therapy and incidence risk of breast cancer: systematic review and meta-analysis

2026 · External reference

Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase

10.1080/09513590701382104 · 2007 · External reference

Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists

10.1093/eurheartj/ehaa1044 · 2021 · External reference

The 2022 hormone therapy position statement of The North American Menopause Society

10.1097/gme.0000000000002028 · 2022 · External reference

Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis

10.1001/jamacardio.2016.2415 · 2016 · External reference

The benefits and risks of menopause hormone therapy for the cardiovascular system in postmenopausal women: a systematic review and meta-analysis

10.1186/s12905-023-02788-0 · 2024 · External reference

Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses

10.1097/gme.0000000000002335 · 2024 · External reference

Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000

10.1016/s0015-0282(01)01699-5 · 2001 · External reference

Estrogen replacement therapy, atherosclerosis, and vascular function

10.1016/s0008-6363(01)00466-7 · 2002 · External reference

Effects of low-dose versus placebo or conventional-dose postmenopausal hormone therapy on variables related to cardiovascular risk: a systematic review and meta-analyses of randomized clinical trials

10.1210/jc.2014-3301 · 2015 · External reference

Menopausal hormone therapy and cardiovascular disease: the role of formulation, dose, and route of delivery

10.1210/clinem/dgab042 · 2021 · External reference

Menopause and MHT in 2024: addressing the key controversies – an International Menopause Society White Paper

10.1080/13697137.2024.2394950 · 2024 · External reference

Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial

10.1136/bmj-2023-078784 · 2024 · External reference

Progression rates of carotid intima-media thickness and adventitial diameter during the menopausal transition

10.1097/gme.0b013e3182611787 · 2013 · External reference

Menopause-associated risk of cardiovascular disease

10.1530/ec-21-0537 · 2022 · External reference

Menopause versus chronologic aging: their roles in women's health

10.1097/gme.0000000000001143 · 2018 · External reference

Cardiovascular health in the menopause transition: a longitudinal study of up to 3892 women with up to four repeated measures of risk factors

10.1186/s12916-022-02454-6 · 2022 · External reference

Age at natural menopause and mortality: a survival analysis of elderly residents of São Paulo, Brazil

10.1016/j.maturitas.2018.08.012 · 2018 · External reference

Age at menopause and risk of heart failure and atrial fibrillation: a nationwide cohort study

10.1093/eurheartj/ehac364 · 2022 · External reference

Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data

10.1016/s2468-2667(19)30155-0 · 2019 · External reference